OUR VISION IS TO REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES WORLDWIDE.

Our Successes

  1. GAFFI has estimated the global burden of serious fungal infections for 5.6 billion people (80% of the world’s population) including Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Dominican Republic, Egypt, France, Germany, Greece, Guatemala, Hungary, India, Indonesia, Iran, Iraq, Ireland, Israel, Jamaica,Jordan, Kenya, Madagascar, Mexico, Mongolia, Mozambique, Nepal, Netherlands, New Zealand, Nigeria, Pakistan, Philippines, Portugal, Russia, Saudi Arabia, Senegal, Serbia, Singapore, South Korea, Spain, Sri Lanka, Tanzania, Thailand, Trinidad and Tobago, Uganda, the UK, Ukraine, Uruguay, Venezuela, Vietnam and Zambia.
  2. “Successfully lobbied the WHO to place amphotericin B and flucytosine on the Essential Medicines List to treat cryptococcal meningitis and other life-threatening fungal infections, in a coalition with other agencies including US Centres for Disease Control, attendees from LIFE, WHO, Medicines Sans Frontieres (MSF), Clinton Health Access and numerous universities and public health institutions.”  View selection and use of Essential Medicines.
  3.  Launched  the 10 year Roadmap ‘95-95 by 2025’ at ISHAM conference in Melbourne, calling on all national governments and public health agencies to reduce the toll of death and blindness from fungal diseases. 95-95 means 95 percent of patients with life or sight-threatening fungal disease will be  diagnosed and 95 percent treated by 2025. GAFFI proposed a target of reducing AIDS deaths to under 500,000 by 2020, which has been adopted by UNAIDS as a key target 10 year ’95-95 by 2025′ GAFFI Roadmap.
  4. GAFFI has successfully lobbied the World Medical Association to adopt a statement addressed to governments on the need for improved access to diagnostics and treatments for fungal diseases, including the development of training for personnel in  laboratories and for physicians. They also encouraged members to undertake and support epidemiological studies. [WMA statement].
  5. GAFFI’s president has contributed the world’s first clinical guidelines for chronic pulmonary aspergillosis and contributed to the Infectious Diseases Society of America updated guidelines for aspergillosis. View
  6. GAFFI has drafted the revisions to the International Classification of Diseases (currently ICD10) to be incorporated into ICD11, in collaboration with the WHO. This is crucial to collection of data internationally, as data is coded using ICD codes all over the world.
  7. GAFFI has applied to the WHO to have itraconazole placed on the Essential Medicines List.
  8. Advocacy has been initiated by GAFFI with the World Health Organization, UNAIDS, the Global Fund to fight AIDS, Tuberculosis and Malaria, MSF, and others. The GFATM has agreed to fund co-infections in AIDS as part of its portfolio.
  9. GAFFI has developed a national ‘Fungal Diseases’ development plan for Kenya, India and for China and is implementing a national program of fungal disease diagnosis and management in AIDS in Guatemala.
  10. Prospective epidemiology studies of chronic pulmonary aspergillosis after TB, in HIV positive and negative patients, and smear negative TB concluded- northern Uganda (Gulu), with GAFFI support. Preparing to publish.
  11. Supported the cryptococcal disease access programme (CryptoMAG), a collaboration between the WHO (HIV Treatment and Care), CDC (Mycotic Diseases Branch), MSF (Access Campaign), Clinton Health Access Initiative and Management Sciences for Health (Technical Strategy and Quality Center for Pharmaceutical Management).
  12. Supported the development of the Histoplasmosis Action Group (HistoAG) a collaboration between numerous clinicians and researchers, the US Centers for Disease Control, Caribbean Public Health Agency and Prevention and the Pan-American Health Organisation. View
  13. GAFFI’s global estimate of recurrent thrush in women is far advanced (see the map here).
  14. Work has started (University of  Manchester) on the fungal keratitis ‘eye drops’ to immediately visualise hyphae or yeasts cells in the eye.
  15. Development work on a simple and inexpensive method for DNA extraction from sputum for Pneumocystis diagnosis is in progress.
  16. Documented the availability and cost of generic antifungals in almost all countries (see the maps here).
  17. Influenced the Antimicrobial Resistance group at the World Health Organisation to prepare to collect antifungal resistance data in Candida and Aspergillus from across the world, on an annual basis.